FEP Medical Policy Manual

FEP 6.01.06 Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography

Effective Policy Date: January 1, 2021
Original Policy Date: June 2012

Related Policies:
- 6.01.20 - Cardiac Applications of Positron Emission Tomography Scanning
- 6.01.26 - Oncologic Applications of Positron Emission Tomography Scanning
- 6.01.51 - Interim Positron Emission Tomography Scanning in Oncology to Detect Early Response During Treatment
- 6.01.55 - Beta-Amyloid Imaging With Positron Emission Tomography for Alzheimer Disease

Description

Positron emission tomography (PET) images biochemical and physiologic functions by measuring concentrations of radioactive chemicals that have been partially metabolized in a particular region of the body. Radiopharmaceuticals used for PET are generated in a cyclotron (nuclear generator) and then introduced into the body by intravenous injection or respiration.

PET scans coupled position-emitting radionuclide tracers to other molecules, such as glucose, ammonia, or water. The radionuclide tracers simultaneously emit 2 high-energy photons in opposite directions that can be simultaneously detected (referred to as coincidence detection) by a PET scanner, which comprises multiple stationary detectors that encircle the region of interest.

A variety of tracers are used for PET scanning, including oxygen 15, nitrogen 13, carbon 11, and fluorine 18. The radiotracer most commonly used in oncology imaging has been fluorine 18, coupled with fluorodeoxyglucose (FDG), which has a metabolism related to...
glucose metabolism. While FDG has traditionally been used in cancer imaging, it potentially has many other applications.

**OBJECTIVE**

The objective of this evidence review is to determine whether use of fluorine 18 fluorodeoxyglucose positron emission tomography improves the net health outcome in individuals with epilepsy, suspected chronic osteomyelitis, suspected Alzheimer disease, suspected large vessel vasculitis, and other non-cardiac and non-oncologic conditions (eg, central nervous system, pulmonary, and musculoskeletal diseases).

**POLICY STATEMENT**

Positron emission tomography (PET) using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) may be considered *medically necessary* in:

1. The assessment of select patients with epileptic seizures who are candidates for surgery (see Policy Guidelines section)
2. The diagnosis of chronic osteomyelitis.

The use of FDG-PET for all other miscellaneous indications is *investigational*, including, but not limited to:

- Central Nervous System Diseases
  - Autoimmune disorders with central nervous system manifestations, including:
    - Behet syndrome
    - lupus erythematosus
  - Cerebrovascular diseases, including:
    - arterial occlusive disease (arteriosclerosis, atherosclerosis)
    - carotid artery disease
    - cerebral aneurysm
    - cerebrovascular malformations (arteriovenous malformation and Moya-Moya disease)
    - hemorrhage
    - infarct
    - ischemia
  - Degenerative motor neuron diseases, including:
    - amyotrophic lateral sclerosis
    - Friedreich ataxia
    - olivopontocerebellar atrophy
    - Parkinson disease
    - progressive supranuclear palsy

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
- Shy-Drager syndrome
- spinocerebellar degeneration
- Steele-Richardson-Olszewski syndrome
- Tourette syndrome

- Dementias, including:
  - Alzheimer disease
  - multi-infarct dementia
  - Pick disease
  - frontotemporal dementia
  - dementia with Lewy bodies
  - presenile dementia

- Demyelinating diseases, such as multiple sclerosis

- Developmental, congenital, or inherited disorders, including:
  - adrenoleukodystrophy
  - Down syndrome
  - Huntington chorea
  - kinky-hair disease (Menkes disease)
  - Sturge-Weber syndrome (encephalofacial angiomatosis) and the phakomatoses

- Miscellaneous
  - chronic fatigue syndrome
  - sick building syndrome
  - posttraumatic stress disorder

- Nutritional or metabolic diseases and disorders, including:
  - acanthocytosis
  - hepatic encephalopathy
  - hepatolenticular degeneration
  - metachromatic leukodystrophy
  - mitochondrial disease
  - subacute necrotizing encephalomyelopathy

- Psychiatric diseases and disorders, including:
  - affective disorders
• depression
• obsessive-compulsive disorder
• psychomotor disorders
• schizophrenia

○ Pyogenic infections, including:
  • aspergillosis
  • encephalitis

○ Substance abuse, including the central nervous system effects of alcohol, cocaine, and heroin

○ Trauma, including brain injury and carbon monoxide poisoning

○ Viral infections, including:
  • HIV/AIDS
  • AIDS dementia complex
  • Creutzfeldt-Jakob disease
  • progressive multifocal leukoencephalopathy
  • progressive rubella encephalopathy
  • subacute sclerosing panencephalitis

○ Mycobacterium infection

○ Migraine

○ Anorexia nervosa

○ Assessment of cerebral blood flow in newborns
  • Vegetative vs locked-in syndrome

• Pulmonary Diseases
  ○ Adult respiratory distress syndrome
  ○ Diffuse panbronchiolitis
  ○ Emphysema
  ○ Obstructive lung disease
  ○ Pneumonia

• Musculoskeletal Diseases
  ○ Spondylodiscitis
  ○ Joint replacement follow-up

• Other

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
Giant cell arteritis
- Vasculitis
- Vascular prosthetic graft infection
- Inflammatory bowel disease
- Sarcoidosis
- Fever of unknown origin
- Inflammation of unknown origin.

**POLICY GUIDELINES**

In patients with epileptic seizures, appropriate candidates are patients with complex partial seizures who have failed to respond to medical therapy and have been advised to have a resection of a suspected epileptogenic focus located in a region of the brain accessible to surgery. Further, for the purposes of this review, conventional noninvasive techniques for seizure localization must have been tried with results suggesting a seizure focus but not sufficiently conclusive to permit surgery. The purpose of the positron emission tomography (PET) examination should be to avoid subjecting the patient to extended preoperative electroencephalographic recording with implanted electrodes or to help localize and minimize the number of sites for implanted electrodes to reduce the morbidity of that procedure.

A PET scan involves 3 separate activities: (1) manufacture of the radiopharmaceutical, which may be manufactured on site or at a regional center with delivery to the institution performing PET; (2) actual performance of the PET scan; and (3) interpretation of the results.

**BENEFIT APPLICATION**

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

**FDA REGULATORY STATUS**

Following the U.S. Food and Drug Administration's (FDA) approval of the Penn-PET in 1989, a number of PET scan platforms have been cleared by the FDA through the 510(k) process. These systems are intended to aid in detecting, localizing, diagnosing, staging and restaging of lesions, tumors, disease and organ function for the evaluation of diseases, and disorders such as, but not limited to, cardiovascular disease, neurologic disorders, and cancer. The images produced by the system can aid in radiotherapy treatment planning and interventional radiology procedures.

PET radiopharmaceuticals have been evaluated and approved as drugs by the FDA for use as diagnostic imaging agents. These radiopharmaceuticals are approved for specific conditions.

In December 2009, the FDA issued guidance for Current Good Manufacturing Practice for PET drug manufacturers; and, in August 2011, issued similar Current Good Manufacturing Practice guidance for small businesses compounding radiopharmaceuticals. An additional final guidance document, issued in December 2012, required all PET drug manufacturers and compounders to operate under an approved new drug application (NDA) or abbreviated NDA, or investigational new drug application, by December 12, 2015.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
In 1994, the FDG radiotracer was originally approved by the FDA through the NDA (20-306) process. The original indication was for "the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures." Added indications in 2000 were for "Assessment of glucose metabolism to assist in the evaluation of malignancy..." and "Assessment of patients with coronary artery disease and left ventricular dysfunction...."

Multiple manufacturers have approved NDAs for FDG.4

See related evidence reviews 6.01.26 and 6.01.51 for oncologic indications and 6.01.20 for cardiac indications for FDG.

**RATIONALE**

**Summary of Evidence**

For individuals who have epileptic seizures who are candidates for surgery who have positron emission tomography (PET) using fluorine 18 fluorodeoxyglucose ([FDG]-PET), the evidence includes systematic reviews (following the publication of 3 TEC Assessments). Relevant outcomes are symptoms, change in disease status, functional outcomes, quality of life (QOL), hospitalizations, medication use, and resource utilization. The TEC Assessments and Program in Evidence-based Care PET recommendation report all concluded that FDG-PET accurately localizes the seizure focus compared with appropriate reference standards. A recent systematic review suggested it was difficult to discern the incremental value of FDG-PET in patients who have foci well localized by ictal scalp electroencephalography and magnetic resonance imaging. The evidence on whether FDG-PET has a predictive value for a good surgical outcome is mixed. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have suspected chronic osteomyelitis who receive FDG-PET, the evidence includes meta-analyses and a prospective study published after the meta-analyses. Relevant outcomes are test accuracy and validity, other test performance measures, change in disease status, functional outcomes, QOL, and hospitalizations. One systematic review and meta-analysis from 2013 of 9 studies revealed that FDG-PET and FDG-PET plus computed tomography were useful for diagnosing suspected osteomyelitis in the foot of patients with diabetes. The results of another meta-analysis (2005) showed that FDG-PET was the most accurate mode (pooled sensitivity, 96%; pooled specificity, 91%) for diagnosing chronic osteomyelitis. The results appear to be robust across fairly diverse clinical populations, which strengthen the conclusions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have suspected Alzheimer disease (AD) who receive FDG-PET to diagnose the disease, the evidence includes systematic reviews of observational studies. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, QOL, and hospitalizations. The studies included in the reviews were generally of poor quality. There is no standard cutoff for PET positivity for diagnosing AD, and many studies have not included postmortem confirmation of AD as the reference standard, leading to uncertainty about estimates of performance characteristics. FDG-PET may have high sensitivity and specificity for diagnosing AD, but there is little evidence comparing the performance characteristics of clinical diagnosis using PET with the clinical diagnosis not using PET; therefore, the incremental value of adding PET to the standard clinical diagnosis is unclear. No studies have reported on clinical outcomes of patients diagnosed with and without FDG-PET. For individuals who have suspected AD who receive FDG-PET to determine the prognosis of their disease and to differentiate the disease from other dementias, the evidence includes systematic reviews of observational studies and a retrospective study assessing clinical utility. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, QOL, and hospitalizations. The studies included in the reviews were generally of poor quality. The evidence is insufficient to determine the effects of the technology on health outcomes for these indications.

For individuals who have suspected large vessel vasculitis who receive FDG-PET, the evidence includes 5 systematic reviews of observational studies and a subsequent observational study. Relevant outcomes are test accuracy and validity, other test performance measures, symptoms, morbidity events, QOL, hospitalizations, and treatment-related morbidity. Most studies included in the reviews were small and lacked controls. The reported performance characteristics were heterogeneous but reviewers were unable to determine the source of heterogeneity. Studies comparing PET with the true reference standard of biopsy or angiography are rare. There are no consensus criteria to define the presence of vascular inflammation by FDG-PET in large vessel vasculitis, and different parameters with visual and semiquantitative methods have been reported. Studies demonstrating changes in management based on PET results or...
improvements in clinical outcomes are lacking. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have diverse non-cardiac or non-oncologic conditions (eg, central nervous system, pulmonary, and musculoskeletal diseases) who receive FDG-PET, the evidence includes several systematic reviews. Relevant outcomes are overall survival, symptoms, change in disease status, functional outcomes, health status measures, QOL, hospitalizations, medication use, and resource utilization. Many studies cited in the reviews were small, retrospective, and published in the 1990s to early 2000s; further, many studies did not directly compare a modality with another in the same patient group—nor did they correlate PET results in individual patients with improved clinical outcomes. Additional studies are needed to demonstrate FDG-PET results can change management, and therefore improve patient outcomes to support the utility of FDG-PET. The evidence is insufficient to determine the effect of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

American Academy of Neurology

Evidence-based practice parameters from the American Academy of Neurology are summarized in Table 1.

Table 1. Practice Parameters on Diagnosis of Dementia

<table>
<thead>
<tr>
<th>Practice Parameter</th>
<th>Date</th>
<th>PET Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis of dementia</td>
<td>2004: reaffirmed; update in progress</td>
<td>PET imaging not recommended for routine use in diagnostic evaluation of dementia (LOR: moderate clinical certainty)</td>
</tr>
<tr>
<td>Early detection of dementia</td>
<td>2003: reaffirmed; retired 2017</td>
<td>Not addressed</td>
</tr>
<tr>
<td>Diagnosis of new-onset PD</td>
<td>2006: reaffirmed; retired 2013</td>
<td>Evidence insufficient to support or refute FDG-PET as a means of distinguishing PD from other parkinsonian syndromes</td>
</tr>
<tr>
<td>Evaluation of depression, psychosis, and dementia in PD</td>
<td>2006; retired 2018</td>
<td>Not addressed</td>
</tr>
<tr>
<td>Mild cognitive impairment</td>
<td>2001; 2017; 2018</td>
<td>Not addressed</td>
</tr>
</tbody>
</table>

---

American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) (2019) published evidence-based, consensus guidelines on the diagnosis and prevention of periprosthetic joint infections. AAOS’s recommendation regarding fluorine 18 fluoride-18-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is that there is limited strength evidence supporting the use of 18F-FDG PET/CT to aid in the diagnosis of periprosthetic joint infections. The strength of the recommendation was rated as “limited,” which was described as “Evidence from two or more ‘Low’ quality studies with consistent findings or evidence from a single ‘Moderate’ quality study recommending for or against the intervention or diagnostic test or the evidence is insufficient or conflicting and does not allow a recommendation for or against the intervention.”

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
American College of Radiology

Evidence and consensus-based appropriateness criteria from the American College of Radiology are summarized in Table 2.

### Table 2. Appropriateness Criteria for Miscellaneous Indications of FDG-PET/CT

<table>
<thead>
<tr>
<th>Appropriateness Criteria</th>
<th>Last Reviewed</th>
<th>FDG-PET/CT Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected osteomyelitis, septic arthritis, or soft tissue infection (excluding spine and diabetic foot)</td>
<td>2017</td>
<td>Usually not appropriate for (1) suspected osteomyelitis with soft tissue or juxta-articular swelling with cellulitis and a skin lesion, injury, wound, ulcer, or blister; or (2) suspected osteomyelitis with pain and swelling or cellulitis associated with site of previous nonarthroplasty hardware. Usually not appropriate for suspected osteomyelitis with soft-tissue or juxta-articular swelling with a history of surgery, though &quot;this is promising new technology but data are limited.&quot;</td>
</tr>
<tr>
<td>Diagnosis of dementia</td>
<td>2001, reaffirmed 2004; revised 2019</td>
<td>May be appropriate for: (1) initial imaging for cognitive decline, suspected Alzheimer disease; (2) initial imaging of suspected frontotemporal dementia; and (3) initial imaging of suspected dementia with Lewy bodies. Usually not appropriate as initial imaging for suspected vascular dementia.</td>
</tr>
<tr>
<td>Movement Disorders and Neurodegenerative Diseases</td>
<td>2019</td>
<td>May be appropriate as initial imaging for rapidly progressive dementia, suspected Creutzfeldt-Jakob disease; usually not appropriate for chorea, suspected Huntington disease; may be appropriate for initial imaging of parkinsonian syndromes; usually not appropriate for initial imaging of suspected neurodegeneration with brain iron accumulation; usually not appropriate for initial imaging of suspected motor neuron disease</td>
</tr>
<tr>
<td>Dementia and movement disorders</td>
<td>2016</td>
<td>May be appropriate in patients with possible or probable AD and to differentiate suspected FTD, LBD, CJD, or vascular dementia; usually not appropriate in patients with suspected HD, clinical features of PD or hemochromatosis, or motoneuron disease</td>
</tr>
<tr>
<td>Imaging after total knee arthroplasty</td>
<td>2017</td>
<td>Usually not appropriate for routine follow-up of asymptomatic patient, in work-up for suspected periprosthetic infection, or for evaluation of prosthetic loosening</td>
</tr>
<tr>
<td>Seizures and epilepsy</td>
<td>2014; revised 2019</td>
<td>Usually appropriate for surgical planning in known seizure disorder; usually not appropriate for new-onset seizure, whether unrelated to trauma or with a history of trauma; may be appropriate (disagreement) for known seizure disorder with unchanged seizure semiology; may be appropriate for known seizure disorder with change in seizure semiology or new neurologic deficit or no return to previous neurologic baseline; may be appropriate (disagreement) for known seizure disorder with a history of trauma</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>2014; revised 2019</td>
<td>Usually not appropriate</td>
</tr>
<tr>
<td>Fever without source - child</td>
<td>2015</td>
<td>May be appropriate. This procedure should not be used as the initial study. Consider if extensive clinical and imaging work-up is negative.</td>
</tr>
<tr>
<td>Suspected osteomyelitis of the foot in patients with DM</td>
<td>2012; revised 2019</td>
<td>Usually not appropriate for initial imaging. May be appropriate for soft-tissue swelling with or without ulcer, suspected osteomyelitis or early neuropathic arthropathy changes of the foot in patients with DM, suspected osteomyelitis of the foot in patients with DM with or without neuropathic arthropathy, and additional imaging following radiographs.</td>
</tr>
</tbody>
</table>

AD: Alzheimer disease; CJD: Creutzfeldt-Jakob disease; CT: computed tomography; DM: diabetes mellitus; FDG: fluorine 18 fluorodeoxyglucose; FTD: frontotemporal dementia; HD: Huntington disease; LBD: Lewy body disease; LOR: level of recommendation; PD: Parkinson disease; PET: positron emission tomography.

Infectious Diseases Society of America

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
The Infectious Diseases Society of America (IDSA; 2015) published evidence-based, consensus guidelines on the diagnosis and treatment of native vertebral osteomyelitis in adults. The guidelines stated that PET "is highly sensitive for detecting chronic osteomyelitis. A negative PET scan excludes the diagnosis of osteomyelitis, including native vertebral osteomyelitis, as the sensitivity of the test is expected to be very high in view of the high concentration of red marrow in the axial skeleton."

The IDSA (2013) published evidence-based, consensus guidelines on the diagnosis and management of prosthetic joint infections. The guidelines concluded that PET should not be routinely used to diagnose prosthetic joint infection (strength of recommendation: B [based on moderate evidence]; quality of evidence: III [expert opinion and descriptive studies]). These Guidelines have now been archived and replaced by an endorsement of the Clinical Practice Guidelines on the diagnosis and prevention of periprosthetic joint infections issued by AAOS (2019) described above.

The IDSA (2012) published evidence-based, consensus guidelines on the diagnosis and treatment of diabetic foot infections. The guidelines concluded that the role of FDG-PET in evaluating a diabetic foot infection has not been established. These Guidelines have now been archived.

The IDSA (2018) will be publishing guidelines on the diagnosis and management of bone and joint infections in children.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

The Centers for Medicare & Medicaid Services (CMS; 2004) released a national coverage decision for a subset of patients "with a recent diagnosis of dementia and documented cognitive decline of at least 6 months, who meet diagnostic criteria for both [Alzheimer disease] and frontotemporal dementia, who have been evaluated for specific alternative neurodegenerative diseases or causative factors, and for whom the cause of the clinical symptoms remains uncertain."

The national coverage determination for FDG-PET for dementia and neurodegenerative diseases (220.6.13) states that:

"Medicare covers FDG Positron Emission Tomography (PET) scans for either the differential diagnosis of frontotemporal dementia (FTD) and Alzheimer's disease (AD) under specific requirements; OR, its use in a Centers for Medicare & Medicaid Services (CMS)-approved practical clinical trial focused on the utility of FDG PET in the diagnosis or treatment of dementing neurodegenerative diseases." Specific requirements for each indication are clarified in the document.

The national coverage determination for FDG-PET for infection and inflammation (220.6.16) states that:

"The CMS is continuing its national noncoverage of FDG PET for the requested indications. Based upon our review, CMS has determined that the evidence is inadequate to conclude that FDG PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin improves health outcomes in the Medicare populations, and therefore has determined that FDG PET for chronic osteomyelitis, infection of hip arthroplasty, and fever of unknown origin is not reasonable..."

**REFERENCES**


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.


POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2012</td>
<td>New policy</td>
<td>Policy updated with literature search; Sarcoidosis added as not medically necessary indication, no other changes to policy statement.</td>
</tr>
<tr>
<td>June 2013</td>
<td>Replace policy</td>
<td></td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2014</td>
<td>Replace policy</td>
<td>Policy update with literature review. Reference 12 added; no changes to policy statement.</td>
</tr>
<tr>
<td>June 2015</td>
<td>Replace policy</td>
<td>Policy updated with literature review; references 13-14, 19, 25, 28-29, 38-40, 42, 47-49, and 51-60 added; reference 50 updated. Vascular prosthetic graft infection, fever of unknown origin, and inflammation of unknown origin added as not medically necessary indications. Acanthocytosis and assessment of cerebral blood flow in newborns revised but no other changes to policy statements.</td>
</tr>
<tr>
<td>December 2016</td>
<td>Replace policy</td>
<td>Policy updated with literature review; references 1-15, 19-21, 32, 39, 44, and 58 added. Policy statements unchanged. Added &quot;Fluorodeoxyglucose F 18&quot; to the title and &quot;FDG&quot; to the investigational statement.</td>
</tr>
<tr>
<td>December 2018</td>
<td>Replace policy</td>
<td>Policy updated with literature review through July 10, 2018; references 28 and 72 added; reference 18 updated. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2019</td>
<td>Replace policy</td>
<td>Policy updated with literature review through July 8, 2019; references added. Policy statements unchanged.</td>
</tr>
<tr>
<td>December 2020</td>
<td>Replace policy</td>
<td>Policy updated with literature review through July 24, 2020; references added. Policy statements unchanged.</td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.